Navigation Links
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Date:2/12/2008

CAMBRIDGE, Mass., Feb. 12 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer.

"We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead product, XMT-1001, and our second product, XMT-1107, will be significant."

Dr. Lowinger has over fifteen years of experience in the pharmaceutical industry and brings a wealth of international experience to his new role in leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in a variety of indications. Most notably, he led the team that discovered and advanced Nexavar(R) (sorafenib), an anti-cancer agent that is approved for indications including renal and hepatocellular cancer, with Phase III studies underway in non-small-cell lung and other cancers. Later, as the VP and Department Head of Chemistry Research in West Haven, he managed a department of scientists in the disciplines of medicinal, analytical, computational, combinatorial and synthetic chemistry, focused on the discovery and clinical proof-of-concept of new therapeutics for the treatment of cancer, diabetes and obesity. He has most recently been VP of Chemistry and Pharmaceutical Sciences at Angiotech Pharmaceuticals where he managed a multidisciplinary team of scientists focused on developing polymer-based pharmaceutical products for local administration as well as medical devices incorporating pharmaceutical agents. Dr. Lowinger has a BSc in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia in Vancouver, Canada.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)... Ames, Iowa (PRWEB) , ... December 08, 2016 , ... ... of asynchronous approvals for biotech crops. The authors focus on the economic effects in ... the global approval of new biotech crops and the resultant risk of low level ...
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   ... identification and object recognition technologies, today released ... for fingerprint recognition solutions that run on ... fingerprint template using less than 128KB of ... compact devices that have limited on-board resources, ...
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):